A Phase 1, Randomized, Double-Blind, Multiple-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of CD101 Injection in Healthy Subjects

Trial Profile

A Phase 1, Randomized, Double-Blind, Multiple-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of CD101 Injection in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs Rezafungin (Primary)
  • Indications Aspergillosis; Candidaemia; Candidiasis
  • Focus Adverse reactions
  • Sponsors Cidara Therapeutics
  • Most Recent Events

    • 19 Mar 2018 Results assessing population pharmacokinetic analyses for rezafungin efficacy using pooled data from two phase 1 studies, were published in the Antimicrobial Agents and Chemotherapy.
    • 06 Dec 2016 Results of PK-pharmacodynamic data analysis from two phase I dose-escalation studies (NCT02516904 and NCT02551549), presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 05 Dec 2016 Safety results from two phase I, dose-escalation studies (NCT02516904 and NCT02551549), published in the Antimicrobial Agents and Chemotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top